News After internal setbacks, Pfizer buys obesity player Metsera Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.
News Biogen buys CNS delivery specialist Alcyone Therapeutics Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.
News Roche poised to buy MASH drug developer 89bio for $3.5bn Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.
News Rumour mill has Camurus buying partner Braeburn Camurus is said to be in talks to acquire US partner Braeburn in a deal that would give it control of their product for treating opioid use disorder.
News Zentiva set to change hands in €4.1bn private equity deal Ex-Sanofi generics company Zentiva is poised for a sale by current owner Advent International to US investment group GTCR, says a media report.
News Novartis nabs cardio drug with $1.4bn Tourmaline buy Novartis has bulked up in cardiology with a $1.4bn takeover of Tourmaline Bio and its drug for atherosclerotic cardiovascular disease (ASCVD).
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
